Bristol-Myers (BMY), AstraZeneca (AZN) Report Significant Data from Dapagliflozin Phase 3 in HbA1c Reduction for Type 2 Diabetes Patients
Go back to Bristol-Myers (BMY), AstraZeneca (AZN) Report Significant Data from Dapagliflozin Phase 3 in HbA1c Reduction for Type 2 Diabetes Patients| ASTRAZENECA PLC (NASDAQ: AZN) | Delayed: 92.77 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $92.77 | 52 Week High | $35.04 | |||
| Open | $92.77 | 52 Week Low | $26.97 | |||
| Day High | $92.77 | P/E | N/A | |||
| Day Low | $92.77 | EPS | $0.00 | |||
| Volume | 1,670,010 | |||||
| Bristol-Myers Squibb (NYSE: BMY) | Delayed: 65.31 +0.45 (0.69%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $64.86 | 52 Week High | $77.12 | |||
| Open | $65.00 | 52 Week Low | $49.03 | |||
| Day High | $65.66 | P/E | 42.41 | |||
| Day Low | $63.53 | EPS | $1.54 | |||
| Volume | 14,579,524 | |||||
